Whereas some studies in experimental models of Parkinson’s and Alzheimer’s disease suggest that it can contribute to dopaminergic degeneration and Tau phosphorylation [74,75], others advocate neuroprotection through different mechanisms [76,77]. This evidence concerns the gene MAPT and Parkinson disease.